Biomarin Pharmaceutical Inc (BMRN)
83.73
-7.47
(-8.19%)
USD |
NASDAQ |
Apr 25, 09:59
Biomarin Pharmaceutical Free Cash Flow: 51.65M for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| December 31, 2023 | 51.65M |
| September 30, 2023 | 31.29M |
| June 30, 2023 | 40.91M |
| March 31, 2023 | 21.77M |
| December 31, 2022 | 44.36M |
| September 30, 2022 | 40.76M |
| June 30, 2022 | -4.394M |
| March 31, 2022 | 23.95M |
| December 31, 2021 | 185.31M |
| September 30, 2021 | 165.24M |
| June 30, 2021 | 154.60M |
| March 31, 2021 | 92.32M |
| December 31, 2020 | -52.15M |
| September 30, 2020 | -2.405M |
| June 30, 2020 | -33.74M |
| March 31, 2020 | -89.02M |
| December 31, 2019 | -115.14M |
| September 30, 2019 | -104.35M |
| June 30, 2019 | -141.73M |
| March 31, 2019 | -137.07M |
| December 31, 2018 | -124.41M |
| September 30, 2018 | -156.98M |
| June 30, 2018 | -158.51M |
| March 31, 2018 | -131.12M |
| December 31, 2017 | -207.98M |
| Date | Value |
|---|---|
| September 30, 2017 | -234.48M |
| June 30, 2017 | -266.76M |
| March 31, 2017 | -309.09M |
| December 31, 2016 | -376.22M |
| September 30, 2016 | -494.09M |
| June 30, 2016 | -505.03M |
| March 31, 2016 | -482.17M |
| December 31, 2015 | -447.15M |
| September 30, 2015 | -329.17M |
| June 30, 2015 | -315.49M |
| March 31, 2015 | -319.03M |
| December 31, 2014 | -187.48M |
| September 30, 2014 | -174.56M |
| June 30, 2014 | -163.53M |
| March 31, 2014 | -128.77M |
| December 31, 2013 | -122.53M |
| September 30, 2013 | -85.69M |
| June 30, 2013 | -63.79M |
| March 31, 2013 | -57.47M |
| December 31, 2012 | -26.96M |
| September 30, 2012 | -115.25M |
| June 30, 2012 | -161.97M |
| March 31, 2012 | -139.41M |
| December 31, 2011 | -135.80M |
| September 30, 2011 | -72.13M |
Free Cash Flow Range, Past 5 Years
-141.73M
Minimum
Jun 2019
185.31M
Maximum
Dec 2021
16.27M
Average
23.95M
Median
Mar 2022
Free Cash Flow Benchmarks
| Eli Lilly and Co | -3.152B |
| Merck & Co Inc | 9.143B |
| Pfizer Inc | 4.793B |
| Bristol-Myers Squibb Co | 12.65B |
| Moderna Inc | -3.825B |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 27.48M |
| Cash from Investing (Quarterly) | -64.96M |
| Cash from Financing (Quarterly) | 10.84M |
| Free Cash Flow Per Share (Quarterly) | -0.0489 |
| Free Cash Flow to Equity (Quarterly) | -10.20M |
| Free Cash Flow to Firm (Quarterly) | -9.213M |
| Free Cash Flow Yield | 0.32% |